{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:19:05Z","timestamp":1792819145180,"version":"4.5.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Prostate-specific membrane antigen (PSMA) PET\/CT has become increasingly accepted for imaging prostate cancer (PCa), including its recent use in primary staging. In this case report, we present the case of a 76-year-old man with newly diagnosed PCa. <jats:sup>18<\/jats:sup>F-PSMA-1007 PET\/CT showed minimal PSMA activity in the primary tumor and metastases. However, <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT revealed more avid lesions in primary tumor, metastatic lymph nodes, and bones. Subsequent histopathologic examination confirmed the diagnosis of PCa. These findings suggest that <jats:sup>18<\/jats:sup>F-FAPI-04 may have a potential role in the evaluation of PCa with low PSMA expression in treatment-naive patients.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004825","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:13:03Z","timestamp":1694632383000},"page":"e532-e534","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Fibroblast Activation Protein\u2013Targeted PET\/CT Imaging in a Treatment-Naive Prostate Cancer Patient With Low PSMA Expression"],"prefix":"10.1097","volume":"48","author":[{"given":"Xingyu","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingquan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","year":"2023","journal-title":"Nat Rev Urol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/RLU.0000000000002100","article-title":"Loss of PSMA expression in non-neuroendocrine dedifferentiated acinar prostate cancer","volume":"43","year":"2018","journal-title":"Clin Nucl Med"},{"key":"bib3-20250621","first-page":"131","article-title":"Neuroendocrine differentiation of prostate cancer leads to PSMA suppression","volume":"26","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/RLU.0000000000004315","article-title":"68Ga-FAPI-46 PET\/CT in a metastatic castration-resistant prostate cancer patient with low PSMA expression","volume":"47","year":"2022","journal-title":"Clin Nucl Med"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s00259-019-04623-x","article-title":"Positive FAPI-PET\/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative\/FDG-positive disease","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","article-title":"PSMA PET and radionuclide therapy in prostate cancer","volume":"46","year":"2016","journal-title":"Semin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","article-title":"High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics","volume":"49","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-20-1358","article-title":"Imaging fibroblast activation protein alpha improves diagnosis of metastatic prostate cancer with positron emission tomography","volume":"26","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:15Z","timestamp":1750532775000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":9,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004825","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,7]]}}}